Bicycle Therapeutics plc
HealthcareNASDAQ:BCYC · NASDAQ Global Select
-$0.05 today
Vol 0.76M · Avg 0.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-35.9%
avg -35.6%
ROIC
-37.3%
avg -42.7%
ROA
-30.5%
avg -34.2%
Analysis
ROA is currently the strongest return metric at -30.5% versus its period average of -34.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin Lee | Chief Executive Officer & Executive Director | $1.66M | — | 58 | $611,313.00 | 0.88% |
Michael Skynner | Chief Scientific Officer | $1.00M | — | 57 | $159,562.00 | 0.23% |
Alistair Milnes | Chief Corporate Development Officer | $965,954.00 | — | 52 | $136,717.00 | 0.20% |
Travis Thompson | Chief Financial Officer | $948,767.00 | — | 46 | $65,364.00 | 0.09% |
Jennifer Perry | Chief Operating Officer | $909,050.00 | — | 52 | $92,464.00 | 0.13% |
Michael Charles-Ferguson Hannay | Chief Product & Supply Chain Officer | $698,383.00 | — | 60 | $159,562.00 | 0.23% |
Sir Gregory Paul Winter FMedsci HonFRCP HonFTSE | Co-Founder & Independent Non-Executive Director | $65,000.00 | — | 75 | $196,427.00 | 0.28% |
Phil Jeffrey | Senior Vice President of Pre-Clinical Development | — | — | — | — | — |
Zafar Qadir | Chief Legal Officer & General Counsel | — | — | — | — | — |
Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications | — | — | — | — | — |
Christian Heinis | Scientific Founder | — | — | — | — | — |
Gillian Langford | Head of Clinical and Project Management | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
48
$568,257.28
Net Sentiment
$568,257.28
Net selling
Most Active
Thompson Travis Alvin
8 transactions
1–10 of 48
Analysis
Insiders reported 0 buys worth $0.00 and 48 sells worth $568,257.28 over the last 12 months. That adds up to net selling of $568,257.28. Thompson Travis Alvin was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +71.5% | +37.7% (10yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +71.5% over three years. Forward estimates point to Revenue at +37.7% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Who manages BCYC?
Bicycle Therapeutics plc (BCYC) lists 12 active executives. The top listed executive is Michael Skynner, Chief Scientific Officer.
Are BCYC insiders buying or selling?
Recent insider activity shows net buying of $40.69M.
Explore More
Continue the stock analysis
Jump to another research area for this company.